as 05-17-2024 4:00pm EST
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
Founded: | N/A | Country: | United States |
Employees: | N/A | City: | VALENCIA |
Market Cap: | 219.8M | IPO Year: | N/A |
Target Price: | $24.25 | AVG Volume (30 days): | 261.9K |
Analyst Decision: | Buy | Number of Analysts: | 5 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.18 | EPS Growth: | N/A |
52 Week Low/High: | $7.51 - $21.70 | Next Earning Date: | 05-13-2024 |
Revenue: | $51,498,000 | Revenue Growth: | 27.03% |
Revenue Growth (this year): | 58.41% | Revenue Growth (next year): | 39.72% |
RCEL Breaking Stock News: Dive into RCEL Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
MT Newswires
5 days ago
GuruFocus.com
6 days ago
GlobeNewswire
6 days ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
Simply Wall St.
a month ago
Simply Wall St.
2 months ago